Literature DB >> 11435354

Post-exposure prophylaxis for HIV infection after sexual assault: when is it indicated?

C Fong1.   

Abstract

To date there are no published studies on the effectiveness of HIV post-exposure prophylaxis (PEP) after sexual exposure. However, as emergency physicians we are faced with the dilemma of assessing the risk of HIV transmission and providing appropriate care for patients who present to us after sexual assault. Current practice in UK emergency departments and genitourinary clinics varies from trust to trust. There is no direct evidence that HIV PEP after rape prevents transmission or is cost effective. However, there may be certain rape cases where HIV PEP should be prescribed or at least considered. While we wait for more definitive clinical studies, HIV PEP after rape should be considered on a case to case basis. This article aims to provide emergency physicians with current scientific evidence on HIV PEP enabling them to make an informed decision on when HIV PEP is indicated after rape.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435354      PMCID: PMC1725619          DOI: 10.1136/emj.18.4.242

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  11 in total

1.  Is HIV prophylaxis effective for sexual exposures?

Authors:  C Vanchieri
Journal:  Ann Intern Med       Date:  1998-03-15       Impact factor: 25.391

Review 2.  Probabilities of sexual HIV-1 transmission.

Authors:  T D Mastro; I de Vincenzi
Journal:  AIDS       Date:  1996       Impact factor: 4.177

3.  Infectiousness of HIV between male homosexual partners.

Authors:  V DeGruttola; G R Seage; K H Mayer; C R Horsburgh
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

4.  HIV testing, counseling, and prophylaxis after sexual assault.

Authors:  L O Gostin; Z Lazzarini; D Alexander; A M Brandt; K H Mayer; D C Silverman
Journal:  JAMA       Date:  1994-05-11       Impact factor: 56.272

Review 5.  Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault.

Authors:  J D Bamberger; C R Waldo; J L Gerberding; M H Katz
Journal:  Am J Med       Date:  1999-03       Impact factor: 4.965

6.  The care of persons with recent sexual exposure to HIV.

Authors:  M H Katz; J L Gerberding
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

Review 7.  HIV in pregnancy and early childhood.

Authors: 
Journal:  Drug Ther Bull       Date:  1999-09

8.  Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical, and policy considerations.

Authors:  P Lurie; S Miller; F Hecht; M Chesney; B Lo
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

9.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

10.  The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection.

Authors:  G Ippolito; V Puro; G De Carli
Journal:  Arch Intern Med       Date:  1993-06-28
View more
  3 in total

Review 1.  HIV and incarceration: prisons and detention.

Authors:  Ralf Jürgens; Manfred Nowak; Marcus Day
Journal:  J Int AIDS Soc       Date:  2011-05-19       Impact factor: 5.396

2.  Sustainability of an HIV PEP Program for Sexual Assault Survivors: "Lessons Learned" from Health Care Providers.

Authors:  Janice Du Mont; Sheila Macdonald; Terri Myhr; Mona R Loutfy
Journal:  Open AIDS J       Date:  2011-11-30

3.  Piloting community-based medical care for survivors of sexual assault in conflict-affected Karen State of eastern Burma.

Authors:  Mihoko Tanabe; Keely Robinson; Catherine I Lee; Jen A Leigh; Eh May Htoo; Naw Integer; Sandra K Krause
Journal:  Confl Health       Date:  2013-05-21       Impact factor: 2.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.